CL2020002881A1 - Uso de canakinumab - Google Patents

Uso de canakinumab

Info

Publication number
CL2020002881A1
CL2020002881A1 CL2020002881A CL2020002881A CL2020002881A1 CL 2020002881 A1 CL2020002881 A1 CL 2020002881A1 CL 2020002881 A CL2020002881 A CL 2020002881A CL 2020002881 A CL2020002881 A CL 2020002881A CL 2020002881 A1 CL2020002881 A1 CL 2020002881A1
Authority
CL
Chile
Prior art keywords
canakinumab
osteoarthritis
inhibitor
prevention
treatment
Prior art date
Application number
CL2020002881A
Other languages
English (en)
Spanish (es)
Inventor
Mattias Schieker
Linda Mindeholm
Jens Praestgaard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020002881A1 publication Critical patent/CL2020002881A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2020002881A 2018-05-09 2020-11-06 Uso de canakinumab CL2020002881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862669071P 2018-05-09 2018-05-09

Publications (1)

Publication Number Publication Date
CL2020002881A1 true CL2020002881A1 (es) 2021-05-14

Family

ID=63638190

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002881A CL2020002881A1 (es) 2018-05-09 2020-11-06 Uso de canakinumab

Country Status (12)

Country Link
US (1) US20210371511A1 (enExample)
EP (1) EP3790576A1 (enExample)
JP (2) JP2021523894A (enExample)
KR (1) KR20210008847A (enExample)
CN (2) CN119746057A (enExample)
AU (1) AU2018422406A1 (enExample)
BR (1) BR112020022576A2 (enExample)
CA (1) CA3098277A1 (enExample)
CL (1) CL2020002881A1 (enExample)
MX (1) MX2020011909A (enExample)
TW (1) TW201946652A (enExample)
WO (1) WO2019215484A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
PL2848258T3 (pl) 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
HRP20251174T1 (hr) * 2010-11-05 2025-11-21 Novartis Ag Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista
BR112014007253A2 (pt) * 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
US20150203592A1 (en) * 2013-12-02 2015-07-23 Abbvie Inc. Compositions and methods for treating osteoarthritis
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
AU2018287519B2 (en) * 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
CN107723310B (zh) * 2017-10-19 2024-01-09 北京睿诚海汇健康科技有限公司 植物作为宿主在表达卡那抗体中的应用

Also Published As

Publication number Publication date
BR112020022576A2 (pt) 2021-02-09
MX2020011909A (es) 2021-01-29
TW201946652A (zh) 2019-12-16
KR20210008847A (ko) 2021-01-25
AU2018422406A1 (en) 2020-11-12
JP2023071904A (ja) 2023-05-23
CA3098277A1 (en) 2019-11-14
WO2019215484A1 (en) 2019-11-14
EP3790576A1 (en) 2021-03-17
US20210371511A1 (en) 2021-12-02
JP2021523894A (ja) 2021-09-09
JP7713983B2 (ja) 2025-07-28
CN119746057A (zh) 2025-04-04
CN112584857A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CL2020002082A1 (es) Inhibidores pd-1/pd-l1.
PH12021500026A1 (en) Irak degraders and uses thereof
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
MY209468A (en) Masp-2 inhibitors and methods of use
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
EA202092692A1 (ru) Аналоги рапамицина и их применения
ZA202409281B (en) Masp-2 inhibitors and methods of use
CL2017002765A1 (es) El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc).
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
MX2024003178A (es) Anticuerpos contra el lif y usos de los mismos.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
TW201613892A (en) Forms and compositions of an ERK inhibitor
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer